NCT00369239View on ClinicalTrials.gov

Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

November 30, 2007

Conditions
SchizophreniaPsychotic DisordersSchizoaffective Disorder
Interventions
DRUG

risperidone long acting injectable

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT00369239 - Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis | Biotech Hunter | Biotech Hunter